Lilly teams up with PRISM BioLab on protein interaction targets

28 Nov 2023
firstwordpharma.com
License out/inPROTACs
Eli Lilly has reached an agreement to use PRISM BioLab's platform to discover oral inhibitors of protein-protein interaction (PPI) targets. "Our PepMetics technology holds promise to change the current paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules," remarked Dai Takehara, CEO at PRISM, in a company statement Tuesday.
PepMetics are a class of small molecules that mimic 3D structures of alpha-helix and beta-turn, which are peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. According to PRISM, the technology can render previously undruggable PPIs into targets readily druggable with small molecules, while also creating oral alternatives for injectable biologics.
Up to $660 million in milestones
Under the deal, the companies will work together using the PepMetics platform to discover small molecule inhibitors of a PPI target chosen by Eli Lilly. PRISM will receive unspecified upfront payments and is eligible for up to $660 million in preclinical, clinical and commercial development milestones, as well as sales royalties. Eli Lilly may also add up to two more targets to the collaboration and is responsible for clinically developing and commercialising any resulting products.
PepMetics targeting CREB-binding protein/beta-catenin PPIs, licensed to Eisai and Ohara Pharmaceuticals, are in clinical development for cancer and liver disease, respectively. PRISM has also previously struck drug discovery collaborations with Roche and Servier.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.